Patents by Inventor Ifat Rubin-Bejerano
Ifat Rubin-Bejerano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865135Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.Type: GrantFiled: December 5, 2017Date of Patent: January 9, 2024Assignee: Innate Biotherapeutics, LLCInventors: Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao, Eric Steven Furfine
-
Publication number: 20200030360Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.Type: ApplicationFiled: December 5, 2017Publication date: January 30, 2020Inventors: Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao, Eric Steven Furfine
-
Patent number: 10266609Abstract: This invention relates to modifications of ?-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.Type: GrantFiled: May 8, 2015Date of Patent: April 23, 2019Assignee: Innate Biotherapeutics, LLCInventors: James Michael Siedlecki, Gabriel Oscar Reznik, John James Kane, Hua Miao, Arthur F. Kluge, Ifat Rubin-Bejerano
-
Publication number: 20180154014Abstract: The present invention encompasses embodiments in which cetuximab or a related cetuximab antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including cetuximab conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.Type: ApplicationFiled: June 1, 2016Publication date: June 7, 2018Inventors: Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao
-
Publication number: 20170369570Abstract: The present invention includes, among other things, ?-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment. In particular embodiments, the antibody is directed to a surface feature of a T regulatory cell, MDSC, or other immune cell. In certain embodiments, the antibody is directed to T regulatory cells, MDSCs, or other immune cells present in a tumor microenvironment. Compositions including ?-1,6-glucan linked to an antibody directed to a T regulatory cell, MDSC, or other immune cell may be useful, e.g., in the treatment of a tumor or cancer in a subject in need thereof. Accordingly, the present invention provides, among other things, methods and compositions for treatment of a tumor or cancer.Type: ApplicationFiled: January 20, 2016Publication date: December 28, 2017Inventors: Ifat Rubin-Bejerano, Gabriel Oscar Reznik, Zuzana Dostalova, Isabelle Sansal-Castellano
-
Publication number: 20170252365Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: ApplicationFiled: July 26, 2016Publication date: September 7, 2017Inventors: Ifat RUBIN-BEJERANO, Gerald R. FINK, Claudia ABEIJON, Daniel S. KOHANE, Jason E. FULLER, Robert S. LANGER
-
Publication number: 20170081428Abstract: This invention relates to modifications of ?-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response.Type: ApplicationFiled: May 8, 2015Publication date: March 23, 2017Inventors: James Michael Siedlecki, Gabriel Oscar Reznik, John James Kane, Hua Miao, Arthur F. Kluge, Ifat Rubin-Bejerano
-
Publication number: 20160331774Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: ApplicationFiled: July 26, 2016Publication date: November 17, 2016Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer
-
Patent number: 9457047Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: GrantFiled: September 26, 2013Date of Patent: October 4, 2016Assignees: Whitehead Institute, Massachusetts Institute of Technology, Trustees of Boston University, The General Hospital CorporationInventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E Fuller, Robert S. Langer
-
Patent number: 9005903Abstract: The invention is directed to ?1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The ?1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The ?1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated ?1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.Type: GrantFiled: December 11, 2013Date of Patent: April 14, 2015Assignee: ImmuneXcite, Inc.Inventors: Ifat Rubin-Bejerano, Gerald R. Fink
-
Publication number: 20140308238Abstract: The invention is directed to ?1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The ?1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The ?1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated ?1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.Type: ApplicationFiled: December 11, 2013Publication date: October 16, 2014Applicant: ImmuneXcite, Inc.Inventors: Ifat Rubin-Bejerano, Gerald R. Fink
-
Publication number: 20140030277Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicants: Whitehead Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston University, Massachusetts Institute of TechnologyInventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer
-
Patent number: 8617823Abstract: The invention is directed to ?1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The ?1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The ?1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated ?1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.Type: GrantFiled: April 29, 2009Date of Patent: December 31, 2013Assignee: Immunexcite, Inc.Inventors: Ifat Rubin-Bejerano, Gerald R. Fink
-
Patent number: 8580253Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: GrantFiled: November 6, 2007Date of Patent: November 12, 2013Assignees: Whitehead Institute, Massachusetts Institute of Technology, Trustees of Boston University, The General Hospital CorporationInventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Danial S. Kohane, Jason E. Fuller, Robert S. Langer
-
Publication number: 20110177532Abstract: The invention is directed to ?1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The ?1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The ?1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated ?1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.Type: ApplicationFiled: April 29, 2009Publication date: July 21, 2011Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Daniel S. Kohane
-
Publication number: 20110045049Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: ApplicationFiled: November 6, 2007Publication date: February 24, 2011Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Danial S. Kohane, Jason E. Fuller, Robert S. Langer